TY - JOUR
T1 - Albuminuria and Heart Failure
T2 - JACC State-of-the-Art Review
AU - Khan, Muhammad Shahzeb
AU - Shahid, Izza
AU - Anker, Stefan D.
AU - Fonarow, Gregg C.
AU - Fudim, Marat
AU - Hall, Michael E.
AU - Hernandez, Adrian
AU - Morris, Alanna A.
AU - Shafi, Tariq
AU - Weir, Matthew R.
AU - Zannad, Faiez
AU - Bakris, George L.
AU - Butler, Javed
N1 - Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
PY - 2023/1/24
Y1 - 2023/1/24
N2 - Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in cardiovascular diseases, including heart failure (HF). The presence and magnitude of albuminuria confers a strong prognostic association in forecasting risk of incident HF as well as its progression, irrespective of eGFR. Despite the high prevalence of albuminuria in HF, whether it adds incremental prognostic information in clinical practice and serves as an independent risk marker, and whether there are any therapeutic implications of assessing albuminuria in patients with HF is less well-established. In this narrative review, we assess the potential role of albuminuria in risk profiling for development and progression of HF, strengths and limitations of utilizing albuminuria as a risk marker, its ability to serve in HF risk prediction models, and the implications of adopting albuminuria as an effective parameter in cardiovascular trials and practice.
AB - Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in cardiovascular diseases, including heart failure (HF). The presence and magnitude of albuminuria confers a strong prognostic association in forecasting risk of incident HF as well as its progression, irrespective of eGFR. Despite the high prevalence of albuminuria in HF, whether it adds incremental prognostic information in clinical practice and serves as an independent risk marker, and whether there are any therapeutic implications of assessing albuminuria in patients with HF is less well-established. In this narrative review, we assess the potential role of albuminuria in risk profiling for development and progression of HF, strengths and limitations of utilizing albuminuria as a risk marker, its ability to serve in HF risk prediction models, and the implications of adopting albuminuria as an effective parameter in cardiovascular trials and practice.
KW - albuminuria
KW - clinical trials
KW - heart failure
KW - Heart Failure/epidemiology
KW - Cardiovascular Diseases
KW - Glomerular Filtration Rate
KW - Albuminuria/epidemiology
KW - Humans
KW - Risk Factors
KW - Renal Insufficiency, Chronic/epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85145748646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145748646&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2022.10.028
DO - 10.1016/j.jacc.2022.10.028
M3 - Review article
C2 - 36653095
AN - SCOPUS:85145748646
SN - 0735-1097
VL - 81
SP - 270
EP - 282
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 3
ER -